Current study confirms: Metabolic syndrome increases risk for koronare heart illness and diabetes

(openPR) - this not completely surprising result was again substantially confirmed to Meta analysis now by one in the technical periodical diabetes Care to publish. In particular with men starting from 45 years and women starting from 55 years the metabolic syndrome with a strongly increased risk for KHK, thus correlated Arteriosklerose, was cardiac infarct and impact accumulation. Same applies to diabetes. In Germany about each third at the risk threshold lives to the metabolic syndrome. Communist manifesto a metabolic syndrome is reached, if 3 of the following 5 criteria is fulfilled: Predominance (belly extent), easily increased blood sugar, easily increased Cholesterin, easily increased total fats or increased blood pressure. What can one do thus, in order to defuse the ticking time bomb and minimize the Infarktrisiko The number of the factors of risk should be lowered. One of the most important measures in this direction is to be gotten it the factor of risk predominance into the grasp. However already this measure can lower the increased illness risk around approximately 20%, is not sufficient however alone not, around the KHK and diabetes risk on normal measure back urge. In addition further factors of risk must be fought. Here the modern prevention research can help. Factors of risk such as Cholesterin, triglycerides, increased blood sugar and oxidative stress can be concerned today on evidence of based basis with simple natural means. The company Navitum Pharma brought now particularly for humans with metabolic syndrome the product to DiaCor plus on the market. DiaCor plus is a combination product of DiaVitum® and CorVitum® and turns to those, which would like to lower their specific KHK and diabetes risk by control of important factors of risk. DiaCor plus (PZN 0265371) is available in pharmacies.
Further information under www.navitum-pharma.com or Kontaktaufnahme by
Mail under info@navitum.de

Source: Lorenzo C. et al. Diabetes Care, volume. 30 (1), January 2007

Navitum Pharma GmbH
At the water tower 29
65207 Wiesbaden
Tel: 0611-58939458
FAX: 0611-9505753
E-Mail: info@navitum.de
Web: www.navitum-pharma.com

Navitum Pharma develops and sells products of natural substances and micro nutrients for the health care of modern fastidious humans. The products documented and certified all on basis compound by current scientific realizations and studies. These singular rationally scientifically justified products and screening programs are explanation needy and require a competent consultation. Therefore our products and services are discussed exclusively with the physician and pharmacist, over physician and pharmacist recommended and only over the pharmacy driven out. Navitum Pharma works for the receipt of health as partner of physician and pharmacist.

The products of the Vitum line of the Navitum® Pharma are meant as preventive measure - in the sense of primary prevention - or supplementing supporting measure - also in the sense of secondary prevention - for illnesses, which can be affected nourish-medically or chemo+preventively. In addition prevention counts illnesses also ageconditioned by heart cycle illnesses, neoplastischen new formations, striking and eye illnesses, metabolic disturbances, bone and joint illnesses, immunological like. Composition and dosage of the products follow strictly scientific criteria and correspond the study situation in the appropriate area of application.
The following products of the Vitum LINE are available:

CorVitum® for the prevention of heart cycle illnesses
ProVitum® for the prevention of Prostatakarzinomen
DiaVitum® for prevention/support with diabetes mellitus
VasoVitum® for prevention/support with venous insufficiency
MemoVitum® for the prevention of ageconditioned immunological and cognitive changes
ArtVitum® for prevention/support with degenerative joint illnesses
OmVitum® for inflammation inhibition with vegetable Omega-3-Fettsäuren
Additionally afterbiotic®, a product is available for the Vorbeugung and moderating of antibiotics associated diarrheas.

Dieser Artikel wurde veröffentlicht auf
OpenPR - http://openpr.de/news/120017/Aktuelle-Studie-bestaetigt-Metabolisches-Syndrom-erhoeht-Risiko-fuer-koronare-Herzkrankheit-und-Diabetes.html